Today's Date: June 23, 2024
Statement by the Prime Minister on National Indigenous Peoples Day   •   Fairness for Indigenous Peoples in Nova Scotia   •   Government of Canada supports high school students across Canada in developing projects to promote healthy living in their schoo   •   Statement by ministers Pascale St-Onge, Gary Anandasangaree, Patty Hajdu and Dan Vandal on National Indigenous Peoples Day   •   Shop, Sip, and Support Social Justice Programs at Five Keys Furniture Annex in Stockton, California, on Saturday, June 22nd from   •   Freedmen’s Town Community Investment Initiative Launches   •   Susan G. Komen® Warns of Dire Impact from Braidwood Management, Inc. et al. v. Xavier Becerra et al. Ruling That Will Force   •   Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting   •   Statement - Mishkeegogamang Ojibway First Nation celebrates community development achievements and National Indigenous Peoples D   •   SCOTUS Ruling in Rahimi Case Upholds Protections for Domestic Violence Survivors, BWJP Experts Celebrate   •   Maximus Named a Top Washington-Area Workplace by The Washington Post   •   WORK BEGINS ON THE ANWATAN-MIGUAM PROJECT IN VAL-D'OR   •   Produced by Renegade Film Productions/Chameleon Multimedia, Obscure Urban Legend ‘Sweaty Larry’ to Be Invoked for Fi   •   New Research Indicates the Need for Diabetes Continuous Glucose Monitoring to Address Health Disparities   •   Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas   •   Otipemisiwak Métis Government Celebrates the Opening and Ribbon Cutting of Salay Prayzaan Solar Farm   •   Lexus & Amazon Music Present "Destination .Paak - The Lexus GX Remix" on World Music Day   •   Daylu Dena Council celebrates grand opening of multi-purpose building in Lower Post, British Columbia   •   Media Advisory: Arvest Bank Awards $15,000 CARE Award to University District Development Corp.   •   Chinatown Storytelling Centre Opens New Exhibit: Neighbours: From Pender to Hastings
Bookmark and Share



PR Newswire

Company is Poised to Participate in $4B U.S. Adult Urinary Incontinence Market

EDMOND, Okla., May 17, 2024 /PRNewswire/ -- Watkins-Conti Products, Inc. ("Watkins-Conti"), a company that develops innovative and accessible solutions for women's pelvic health, has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Yōni.Fit® Bladder Support ("Yōni.Fit®"). Yōni.Fit® is intended for the temporary management of urine leakage caused by stress urinary incontinence (SUI) in women, 18 years and older.

Company is Poised to Participate in $4B U.S. Adult Urinary Incontinence Market

Manufactured in the U.S. with 100% medical-grade silicone, Yōni.Fit® is a soft vaginal insert that reduces urine leaks without interfering with voluntary urination. Yōni.Fit® is self-administered and can be used during a specific activity or up to 12 hours for general control over symptoms. The FDA clearance represents a substantial milestone in non-surgical options for the temporary management of urinary incontinence, a condition that is estimated to affect about 2 in 3 women in the United States at some point in their lives, negatively impacting quality of life and emotional well-being.

"In my clinical practice, women who experience urine leakage feel they have limited treatment options and desire an alternative to surgery or adult pads," said Eric R. Sokol, MD, Associate Professor of Obstetrics and Gynecology at Stanford Health Care and an investigator in the Yōni.Fit® clinical study.

"My patients with stress urinary incontinence want a solution that is effective and convenient – one that accommodates the reality of their busy lives and does not interfere with voluntary urination," said Karolynn T. Echols, MD, Director and Associate Professor of Female Pelvic Medicine and Reconstructive Surgery at Thomas Jefferson University and an investigator in the Yōni.Fit® clinical study. "The cost and downtime associated with surgery can be prohibitive for some women."

"My lived experience as a new mother with SUI gave me the inspiration for Yōni.Fit®. The options available to me at the time did not complement my lifestyle as a working mom with two small children," said Allison L. Watkins, founder and CEO of Watkins-Conti. "Listening to patients on their journey and innovating accordingly is paramount. I am committed to developing even more solutions for women's pelvic health, using the Yōni.Fit® device as a self-care platform that could potentially include diagnostics and drug delivery."

Fifty-eight (58) participants were enrolled in a randomized, controlled, single blind, multi-center study of Yōni.Fit® in women with SUI. The study was conducted by urogynecologists at Stanford, NYU Langone, and Jefferson Health. Of the participants completing the evaluation phase, a significantly higher percentage experienced clinically meaningful reduction in 12-hour pad weights with the Yōni.Fit® device compared to the control device. Among study participants experiencing adverse events, the severity was mild to moderate; there were no serious adverse events related to Yōni.Fit®.

"I believe Yōni.Fit® will be an appealing and effective self-care solution for patients who value convenience and want to be in control of their pelvic health," said Kate C. Arnold, MD, Chief Medical Officer of Watkins-Conti. "We are committed to helping all women, including those in rural areas and in medically underserved communities, where access to surgery would be challenging."

"With this FDA clearance, Watkins-Conti is now positioned to help this important and underserved market," said Ross Watkins, president of Watkins-Conti.

Yōni.Fit® will be available with a prescription from a primary healthcare provider and may be covered by insurance. Product information is available at Yō

The company has raised nearly $10M from angel investors and VCs. The funds have been directed towards creating a quality management system, protecting the company's robust intellectual property portfolio, conducting clinical trials, biocompatibility and toxicology testing on the devices, and expanding the executive team and expert advisors.

About Watkins-Conti Products, Inc.

Founded by entrepreneur and inventor Allison L. Watkins, Watkins-Conti is an American healthcare company that develops innovative and accessible solutions for women's pelvic health. Watkins-Conti is developing a pipeline of treatments and diagnostics that address women's reproductive, sexual, and pelvic health — with the ultimate goal of getting women everywhere the care they deserve. The company's flagship product, Yōni.Fit®, is the first patient-designed, non-surgical device designed to relieve the symptoms of stress urinary incontinence. Based in Edmond, Oklahoma, Watkins-Conti holds numerous utility patents, design patents, and trademarks in the U.S. and abroad. For more information, visit and LinkedIn.

Media Contact:

Anthony Triana 

Cision View original content to download multimedia:

SOURCE Watkins-Conti Products, Inc.

Back to top
| Back to home page

White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News